Ropivacaine Hydrochloride Patent Expiration
Ropivacaine Hydrochloride is used for pain management. It was first introduced by Fresenius Kabi Usa Llc
Ropivacaine Hydrochloride Patents
Given below is the list of patents protecting Ropivacaine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Naropin | US7857802 | Connector for medical liquid-containing packages and medical liquid-containing packages | Nov 28, 2026 | Fresenius Kabi Usa |
| Naropin | US7828787 | Connector for packaging containing medical fluids and packaging for medical fluids |
Oct 18, 2025
(Expired) | Fresenius Kabi Usa |
| Naropin | US8162915 | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May 23, 2024
(Expired) | Fresenius Kabi Usa |
| Naropin | US8118802 | Connector for packaging containing medical fluids and packaging for medical fluids |
May 18, 2023
(Expired) | Fresenius Kabi Usa |
| Naropin | US5670524 | Methods and compositions for the treatment of pain utilizing ropivacaine |
Sep 23, 2014
(Expired) | Fresenius Kabi Usa |
| Naropin | US5834489 | Methods and compositions for the treatment of pain utilizing ropivacaine |
May 26, 2014
(Expired) | Fresenius Kabi Usa |
Ropivacaine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ropivacaine Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. | CSPC Ouyi Pharmaceutical Co., Ltd. | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. | The Third Xiangya Hospital of Central South University | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |